View Older Stories View More Recent Stories

Aug 6, 2020 09:00AM Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Aug 5, 2020 07:00AM Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EB
Jul 31, 2020 07:12AM Horizon Therapeutics (HZNP) New Topline TEPEZZA Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with TED
Jul 31, 2020 07:00AM New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
Jul 22, 2020 08:07AM Horizon Therapeutics (HZNP) Reports Target Patient Enrollment in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA (pegloticase injection) Co-Prescribed with Methotrexate
Jul 22, 2020 08:00AM Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for Peopl
Jul 13, 2020 08:30AM Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020
Jul 9, 2020 08:39AM Horizon Therapeutics (HZNP) Announces CMS Issues Permanent J-Code for TEPEZZA Effective Oct. 1, 2020
Jul 9, 2020 08:30AM Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
Jul 1, 2020 09:00AM New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health
Jun 3, 2020 08:10AM Horizon Therapeutics (HZNP) Presents Data on KRYSTEXXA (pegloticase injection) Co-Prescribed with Immunomodulator
Jun 3, 2020 08:05AM Horizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
Jun 3, 2020 08:00AM Data Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
May 21, 2020 09:15AM Horizon Therapeutics Named Number One Best Workplace in Chicago
May 21, 2020 08:00AM Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
May 19, 2020 08:00AM Horizon Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2020 09:04AM Horizon Therapeutics (HZNP) Announces New Data on Pharmacokinetic Profile of TEPEZZA Reinforce Labeled Dosing Regimen, Indicating Positive, Consistent Response to Therapy
May 14, 2020 09:00AM New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
May 11, 2020 12:00PM U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
May 6, 2020 07:00AM Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-
Apr 27, 2020 08:10AM Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
Apr 15, 2020 08:00AM Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
Apr 9, 2020 09:00AM Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
Apr 2, 2020 08:11AM Horizon Therapeutics (HZNP) Acquires Curzion Pharmaceuticals
Apr 2, 2020 08:00AM Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Mar 31, 2020 12:03PM Horizon Therapeutics (HZNP) TEPEZZA Significantly Reduces Proptosis Across Patient Subtypes
Mar 31, 2020 12:00PM TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Mar 26, 2020 04:15PM Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Mar 3, 2020 08:00AM Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Feb 28, 2020 10:00AM Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
Feb 28, 2020 08:00AM Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
Feb 27, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Workplaces in Ireland
Feb 26, 2020 07:00AM Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
Feb 18, 2020 08:30AM Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
Feb 18, 2020 08:01AM Horizon Therapeutics (HZNP) Announces FDA Approval of New Dosage Form for PROCYSB
Feb 18, 2020 08:00AM Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
Feb 11, 2020 08:00AM Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
Feb 4, 2020 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Jan 28, 2020 11:10AM Horizon Therapeutics (HZNP) Announces Significant Expansion, Relocation of U.S. Operations
Jan 28, 2020 11:10AM Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
Jan 24, 2020 04:07PM Horizon Therapeutics (HZNP) Announces Changes in Research and Development Organization
Jan 24, 2020 04:05PM Horizon Therapeutics plc Announces Changes in Research and Development Organization
Jan 22, 2020 05:22PM Horizon Therapeutics (HZNP) Reports Publication of Comprehensive Data from Ph. 3 Clinical Trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for Thyroid Eye Disease
Jan 22, 2020 05:20PM The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
Jan 21, 2020 03:06PM Horizon Therapeutics (HZNP) Confirms FDA Approved TEPEZZATM for Treatment of Thyroid Eye Disease
Jan 21, 2020 03:04PM FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
Jan 13, 2020 08:26AM Horizon Therapeutics (HZNP) Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers
Jan 13, 2020 08:25AM Horizon Therapeutics (HZNP) Announces MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA Indicates Significant Improvement in Response Rate
Jan 13, 2020 08:15AM Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
Jan 13, 2020 08:05AM MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
View More Recent Stories View Older Stories